作者
Adam B Mayerson, Ripudaman S Hundal, Sylvie Dufour, Vincent Lebon, Douglas Befroy, Gary W Cline, Staffan Enocksson, Silvio E Inzucchi, Gerald I Shulman, Kitt F Petersen
发表日期
2002/3/1
期刊
Diabetes
卷号
51
期号
3
页码范围
797-802
出版商
American Diabetes Association
简介
We examined the effect of three months of rosiglitazone treatment (4 mg b.i.d.) on whole-body insulin sensitivity and in vivo peripheral adipocyte insulin sensitivity as assessed by glycerol release in microdialysis from subcutaneous fat during a two-step (20 and 120 mU · m−2 · min−1) hyperinsulinemic-euglycemic clamp in nine type 2 diabetic subjects. In addition, the effects of rosiglitazone on liver and muscle triglyceride content were assessed by 1H-nuclear magnetic resonance spectroscopy. Rosiglitazone treatment resulted in a 68% (P < 0.002) and a 20% (P < 0.016) improvement in insulin-stimulated glucose metabolism during the low- and high- dosage−insulin clamps, respectively, which was associated with ∼40% reductions in plasma fatty acid concentration (P < 0.05) and hepatic triglyceride content (P < 0.05). These changes were associated with a 39% increase in extramyocellular lipid content (P < 0.05 …
引用总数
学术搜索中的文章
AB Mayerson, RS Hundal, S Dufour, V Lebon, D Befroy… - Diabetes, 2002